Last edition
News about
Corona Remedies to Expand Bhayla Manufacturing Capacity by 400 Million Units
Corona Remedies Limited has announced an expansion of manufacturing capacity at its Bhayla formulation facility to support rising demand for its products. The expansion will add 400 million units of tablet and capsule capacity, with 240 million units expected to be available for utilisation.
Intas Partners IntegriMedical to Introduce Needle-Free Injection Technology
Intas Pharmaceuticals has signed an exclusive agreement with IntegriMedical, the developer of India’s first needle-free injection system, to introduce the technology for use in in vitro fertilisation and gynaecology treatments across the country.
ABL Bio Secures USD 40 Million Upfront, USD 15 Million Equity Investment From Eli Lilly
ABL Bio, a company focused on bispecific antibody technologies, announced that it will receive a USD 40 million upfront payment under a license, research, and collaboration agreement for its proprietary Grabody platform, along with a USD 15 million equity investment from Eli Lilly and Company.
IPC to Conduct 36th Pharmacovigilance Skill Development Programme in March 2026
The Indian Pharmacopoeia Commission (IPC), the National Coordination Centre (NCC) for the Pharmacovigilance Programme of India (PvPI), will organise the 36th Skill Development Programme (SDP) on Pharmacovigilance (PV) from March 9 to March 13, 2026. The programme will be conducted in online mode.
SN Bioscience's SNB-101 Secures FDA Orphan Drug Designation for Gastric Cancer
SNB-101 is a polymer nanoparticle–based anticancer drug that uses SN-38, a highly potent but extremely insoluble active pharmaceutical ingredient.
Akums Signs MoU with Sharda University Agra to Advance Pharma Research
Akums Drugs & Pharmaceuticals has entered into a Memorandum of Understanding (MoU) with Sharda University, Agra, to collaborate on pharmaceutical research, technology transfer, and skill development, with an emphasis on strengthening the linkage between academic research and industrial application.
Kashiv BioSciences Secures INR 684 Crore to Build Biopharma Facility
Kashiv BioSciences has secured INR 648 crore in financing from Union Bank of India to invest in a state-of-the-art biologics manufacturing facility in Pipan, Gujarat, aimed at strengthening technical capabilities, enhancing global competitiveness, and generating long-term, high-value employment across scientific, technical and operational roles.
ABL Bio Receives Upfront Payment and Equity Investment from Lilly for Grabody Platform
ABL Bio has secured a total of USD 55 million in funding from Lilly, including a USD 40 million upfront payment and a USD 15 million equity investment, under a license, research and collaboration agreement to advance R&D and expand indications for its Grabody platform.
CDSCO Flags 205 Not of Standard Quality Drug Samples in November Despite Data Gaps from States
Even as data submissions were pending from nearly 18 states and five Union Territories, the Central Drugs Standard Control Organisation (CDSCO) reported a total of 205 drug samples as Not of Standard Quality (NSQ) during November 2025.
Windtree Therapeutics to Sell Cardiovascular Pipeline Assets
Windtree Therapeutics has agreed to sell its cardiovascular biotech pipeline assets to Seismic Pharmaceuticals under a deal that includes a potential USD 700,000 contingent payment, transfer of certain development payables, and Windtree retaining a 20 percent share of any future milestone, royalty, or global commercial revenue generated from the assets.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy